RejuvenRx
RejuvenRx Inc. is a preclinical Montreal-based biotech developing small-molecule therapeutics that target cancer stem cells and cellular aging through degradation of the CoREST1 epigenetic complex, with the goal of treating aging oncology patients and aging-associated diseases via future licensing partnerships.
- Company typePrivate
- Founded2020
- HeadquartersMontréal, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What RejuvenRx does
RejuvenRx Inc. is a privately held, preclinical-stage biotechnology company headquartered in Montreal, Quebec, that develops small-molecule targeted therapies addressing both cancer and cellular aging. The company was established in 2023 as a spin-off co-founded by IRICoR and ExCellThera, with technology roots in the Leucegene program and the UM171 discoveries from IRIC's Drug Discovery Unit. Its core scientific platform centers on degrading the CoREST1 epigenetic complex (RCOR1, HDAC1/2, LSD1) through a novel CUL3KBTBD4 Cullin 3 ubiquitin ligase mechanism, combined with proprietary leukemia stem cell culture conditions that enable screening against primary cancer cells and cancer stem cells. The disclosed preclinical pipeline comprises a pyrimidoindole small-molecule series targeting aging frailty, alongside three oncology candidates: an RCOR1 degrader, a Cyclin K degrader, and a metabolism modulator.
RejuvenRx's business model is structured for eventual licensing and royalty revenue rather than near-term product sales, consistent with its pre-revenue, preclinical status. The company pursues an enterprise field sales / business development motion, engaging pharmaceutical companies and research institutions for co-development, licensing, and commercialization of therapeutic candidates. Its primary intended patient populations are aging oncology patients (where cellular aging affects response and tolerance to cancer therapy) and elderly patients with aging-associated diseases such as neurodegeneration and poor wound healing. There are no disclosed pricing models, commercialized products, or named customer accounts.
The company is led by Anne Marinier (CEO; 25+ years in medicinal chemistry, co-founder of IRIC's Drug Discovery Unit, identified UM171, ex-Bristol-Myers Squibb, ex-CTO at ExCellThera), David Millette (Chair; Co-CEO & COO at ExCellThera, ex-Partner at Norton Rose Fulbright), and Guy Sauvageau (Board Member; internationally recognized stem cell biologist, co-founder of ExCellThera). Elizabeth Douville, President & CEO of IRICoR, also sits on the board. The company's funding history consists of a single strategic investment from co-founder IRICoR in January 2023, with the amount undisclosed and no additional institutional investors identified.
RejuvenRx firmographics
Firmographics- Name
- RejuvenRx
- Legal name
- RejuvenRx Inc.
- Website
- https://rejuvenrx.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RejuvenRx Inc. is a preclinical Montreal-based biotech developing small-molecule therapeutics that target cancer stem cells and cellular aging through degradation of the CoREST1 epigenetic complex, with the goal of treating aging oncology patients and aging-associated diseases via future licensing partnerships.
- Ownership category
- akta.pro rank
RejuvenRx industry classification
Industry- Product category
- Biotechnology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where RejuvenRx is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
RejuvenRx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Therapeutic Development and Licensing: Pre-revenue biotech company developing small molecule therapeutics for cancer and aging diseases. Revenue expected to come from licensing deals, partnerships, and eventual product commercialization upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
RejuvenRx product offering
Product offeringCore offering
RejuvenRx develops small molecule-based targeted therapies focused on stem cell biology to address cancer and aging diseases. The pipeline includes preclinical candidates: a Pyrimidoindole series for aging frailty and oncology, an RCOR1 degrader, a Cyclin K degrader, and a metabolism modulator for cancer stem cell targeting. The programs are supported by a proprietary screening platform derived from the Leucegene program that preserves cancer stem cell activities in culture for drug discovery.
Product overview
RejuvenRx is a biotechnology company developing small molecule-based targeted therapies focused on stem cell biology to address cancer and aging. The company's main asset is a series of small molecules that promote tissue regenerative capacity, targeting both aging frailty and cancer. The pipeline includes pre-clinical candidates: Pyrimidoindole series for aging, and RCOR1 degrader, Cyclin K degrader, and Metabolism modulator for oncology. These programs are supported by a novel screening platform derived from the Leucegene program that preserves cancer stem cell activities for drug discovery. The combination delivers precision therapies for aging oncology patients.
Differentiator
Problem solved
Functional benefit
Products and services
- Pyrimidoindole Series
- RCOR1 Degrader
- Cyclin K Degrader
- Metabolism Modulator
Companies that use RejuvenRx
Customer profileSegments2 records
Ideal customer profiles1 record
RejuvenRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
RejuvenRx partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- ExCellTheracoreExCellThera co-founded RejuvenRx alongside IRICoR. Key personnel including CEO Anne Marinier and CSO Guy Sauvageau have leadership roles at ExCellThera. The relationship provides access to shared scientific expertise, particularly in stem cell biology and the UM171 compound development.
- IRIC (Institute for Research in Immunology and Cancer)coreIRIC is the parent institution for IRICoR and the source of the Leucegene program. The drug discovery unit at IRIC, co-founded by Anne Marinier, provides scientific foundation and target identification capabilities.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
RejuvenRx competitors and assessment
Company assessmentMarket position
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
RejuvenRx social profiles
Digital presenceRejuvenRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
RejuvenRx leadership team
Management profileNumber of profiles
Profiles4 records
RejuvenRx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RejuvenRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RejuvenRx
What does RejuvenRx do?
RejuvenRx develops small molecule-based targeted therapies focused on stem cell biology to address cancer and aging diseases. The pipeline includes preclinical candidates: a Pyrimidoindole series for aging frailty and oncology, an RCOR1 degrader, a Cyclin K degrader, and a metabolism modulator for cancer stem cell targeting. The programs are supported by a proprietary screening platform derived from the Leucegene program that preserves cancer stem cell activities in culture for drug discovery.
Is RejuvenRx a public or private company?
RejuvenRx is a private company. It is classified as unknown and is currently operating.
When was RejuvenRx founded?
RejuvenRx was founded in 2020. It employs 1 to 10 people.
Where is RejuvenRx based?
RejuvenRx is headquartered in Montréal, Canada, in the North America region.
How does RejuvenRx make money?
One revenue line is on record: therapeutic Development and Licensing.
Does RejuvenRx have an API?
No public API is recorded for RejuvenRx.
What industry is RejuvenRx in?
RejuvenRx's product category is Biotechnology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 2834.